{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:30:07Z","timestamp":1790386207974,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.leukres.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T17:23:35Z","timestamp":1437672215000},"page":"1109-1116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation"],"prefix":"10.1016","volume":"39","author":[{"given":"Sang Hyuk","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Jeoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Ra","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Uk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.07.006_bib0005","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.07.006_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR- ABL. kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2015.07.006_bib0015","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.07.006_bib0025","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.07.006_bib0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clml.2013.11.002","article-title":"Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib","volume":"14","author":"Lau","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2015.07.006_bib0035","first-page":"144","article-title":"The phenomenon of multi-drug resistance in the treatment of malignant tumors","volume":"36","author":"Vtorushin","year":"2014","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.leukres.2015.07.006_bib0040","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1182\/blood-2010-07-296954","article-title":"Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib","volume":"116","author":"Deenik","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.07.006_bib0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.leukres.2015.07.006_bib0050","first-page":"158","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","author":"Vasconcelos","year":"2010","journal-title":"Cytometry B: Clin. Cytom."},{"key":"10.1016\/j.leukres.2015.07.006_bib0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.leukres.2006.07.016","article-title":"Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice","volume":"31","author":"Vasconcelos","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2015.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.20013","article-title":"Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia","volume":"61","author":"Cavalcanti","year":"2004","journal-title":"Cytometry B. Clin. Cytom."},{"key":"10.1016\/j.leukres.2015.07.006_bib0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/17425255.3.3.363","article-title":"Molecular mechanisms of drug resistance in acute myeloid leukaemia","volume":"3","author":"McLornan","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.leukres.2015.07.006_bib0070","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MPH.0b013e3181a974b3","article-title":"P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia","volume":"31","author":"Brozek","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2015.07.006_bib0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"European leukemia net. response definitions and european leukemianet management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.leukres.2015.07.006_bib0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0145-2126(02)00094-2","article-title":"CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype","volume":"27","author":"Silva","year":"2003","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2015.07.006_bib0085","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0959-8049(94)90187-2","article-title":"Comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes","volume":"30","author":"Twentyman","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2015.07.006_bib0090","unstructured":"Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline\u2014Third Edition. CLSI document C28-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008."},{"key":"10.1016\/j.leukres.2015.07.006_bib0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cbi.2014.06.009","article-title":"Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells","volume":"219","author":"Kosztyu","year":"2014","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.leukres.2015.07.006_bib0100","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3892\/ol.2014.1857","article-title":"ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib","volume":"7","author":"Vivona","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.leukres.2015.07.006_bib0105","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/leu.2014.6","article-title":"MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure","volume":"28","author":"Agrawal","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.07.006_bib0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochemistry (Mosc.)"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615303490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615303490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T16:59:58Z","timestamp":1567011598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615303490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0145212615303490"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.07.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}